Provided by Tiger Trade Technology Pte. Ltd.

Viracta Therapeutics, Inc.

0.0098
0.0000
Volume:- -
Turnover:- -
Market Cap:388.70K
PE:-0.01
High:0.0098
Open:0.0098
Low:0.0098
Close:0.0098
52wk High:0.5800
52wk Low:0.0080
Shares:39.74M
Float Shares:28.69M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1022
EPS(LYR):-1.3219
ROE:-370.13%
ROA:-66.76%
PB:-0.06
PE(LYR):-0.01

Loading ...

BRIEF-Viracta Therapeutics Announces Wind Down Of Operations

Reuters
·
Feb 06, 2025

Viracta Therapeutics Winds Down Operations, Terminates Employees

Dow Jones
·
Feb 06, 2025

Viracta Therapeutics Announces Wind Down of Operations

THOMSON REUTERS
·
Feb 06, 2025

Viracta Therapeutics Inc: Exploring Potential Strategic Alternatives for Its Development Programs

THOMSON REUTERS
·
Feb 06, 2025

Viracta Therapeutics Inc: Appointed Craig Jalbert as CEO, CFO, Sole Member of Board to Implement Wind Down

THOMSON REUTERS
·
Feb 06, 2025

Viracta Therapeutics Shares Decline After Rodman & Renshaw Downgrade

MT Newswires Live
·
Dec 28, 2024

Top Calls on Wall Street: Estee Lauder, ServiceTitan, Tencent Music and More

Tiger Newspress
·
Dec 27, 2024

Viracta Therapeutics Cut to Neutral From Buy by Rodman & Renshaw

Dow Jones
·
Dec 27, 2024

Rodman & Renshaw Downgrades Viracta Therapeutics to Neutral

MT Newswires Live
·
Dec 27, 2024

Viracta Therapeutics Exploring Options, Including Potential Sale; Closes Phase 2 Trial of Nana-val

MT Newswires Live
·
Dec 27, 2024

Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives

Dow Jones
·
Dec 27, 2024

BRIEF-Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives

Reuters
·
Dec 27, 2024

Viracta Therapeutics Announces Closure of Naval-1 Clinical Trial and Exploration of Strategic Alternatives

THOMSON REUTERS
·
Dec 27, 2024

Viracta Therapeutics Inc - to Close Phase 2 Clinical Trial of Nana-Val

THOMSON REUTERS
·
Dec 27, 2024

Viracta Therapeutics Inc - Potential Alternatives Include Merger, Licensing Agreement, Sale

THOMSON REUTERS
·
Dec 27, 2024

Viracta Therapeutics Inc - Closure of Trial Not Due to New Safety Finding

THOMSON REUTERS
·
Dec 27, 2024

Press Release: Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Dow Jones
·
Dec 27, 2024

BRIEF-Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq

Reuters
·
Nov 23, 2024

RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 14, 2024